57 results about "Epithelial barrier" patented technology

The invention provides an apigenin nanoparticle preparation as well as a preparation method and application thereof. The preparation method comprises the following steps: weighing apigenin, dissolving the apigenin in an acetone solution containing a polylactic acid-glycolic acid copolymer, or dissolving the apigenin in an acetone solution containing the polylactic acid-glycolic acid copolymer and Eudragit S100, and uniformly stirring and mixing at room temperature to obtain a mixed solution; dropwise adding the mixed solution into a polyvinyl alcohol solution, carrying out ultrasonic treatment, and removing the solvent to prepare PANPs or PEANPs. The preparation method is simple, and the prepared PANPs and PEANPs are small in particle size and high in encapsulation efficiency, can effectively penetrate through intestinal epithelial barriers and promote internalization of apigenin into cells, have a good slow release characteristic, can remarkably improve the bioavailability of apigenin, and have a good treatment effect on inflammatory bowel diseases. PANPs has a better treatment effect on ulcerative colitis, and PEANPs has a better treatment effect on diffuse colitis.

A method of testing a test substance in an in vitro model of a human tracheobronchial respiratory tract, includes: providing the in vitro model including a cell culture including airway epithelial cells (AECs), a basolateral compartment below the AECs and an apical compartment above the AECs, wherein the AECs form a barrier between the basolateral AND apical compartments; adding the test substance to the apical and / or basolateral compartment; adding a tracer to the basolateral compartment, which is fluorescent, has a molecular weight within 5 kDa of human albumin and is added before, during or after adding the test substance; incubating the cell culture system in a presence of the tracer; collecting at least one sample from the apical compartment; and measuring a fluorescence thereof to determine an effect of the test substance on the AECs. A kit is also disclosed.

The present invention belongs to the field of medicine, and in particular relates to the use of 1,6-anhydro-β-D-glucose in the preparation of drugs for maintaining the integrity of the colon epithelial barrier and crypts and for anti-colitis. The present invention detects the colitis-related metabolite 1,6-anhydro-β-D-glucose by detecting mouse serum, and applies it to mice. It is found that 1,6-anhydro-β-D-glucose can alleviate the weight loss and shortening of colon length in mice, reduce the disease score index (DAI), maintain the integrity of the colon epithelial barrier and crypts, and exert anti-inflammatory effects, thereby alleviating DSS-induced colitis. Therefore, 1,6-anhydro-β-D-glucose is expected to be used in the research and development of related drugs.

Methods and materials relating to cultured choroid plexus organoids comprising: (a) an epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by an epithelium, plus other authentic features and markers.

The invention discloses a method for preparing a VA-ECMO lung injury treatment medicine by using ginkgolide A to regulate YARS1, and relates to the technical field of biological medicine, the method comprises the following steps: by using ginkgolide A as a YARS1 protein regulator, preparing the medicine for treating the VA-ECMO lung injury through virtual screening, binding affinity confirmation and cell efficacy confirmation; wherein the virtual screening is based on a protein structure model of YARS1, and bilobalide A with high affinity binding energy with YARS1 is screened out through molecular docking. It is proved that ginkgolide A can effectively improve the lung ventilation function by regulating YARS1, repair the alveolar epithelial barrier structure and inhibit the inflammatory oxidative stress reaction, and the lung injury treatment effect and clinical transformation safety under the support of VA-ECMO are improved.

The invention relates to an application of an MYOF protein in preparation of a product for preventing, relieving and / or treating acute lung injury. According to the application, the MYOF protein can be combined with GSDMD-NT, and up-regulation of expression of the MYOF protein can effectively inhibit activation of GSDMD and pyroptosis mediated by GSDMD, so that the MYOF protein has an application prospect in preparation of products for preventing, relieving and / or treating acute lung injury, and the technical problem that alveolar epithelial barriers are easily damaged during treatment can be solved.

Methods and materials relating to cultured choroid plexus organoids comprising: (a) an epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by an epithelium, plus other authentic features and markers.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine nano preparation and application thereof in preparation of a medicine for preventing / treating PM2.5 induced lung injury. The invention provides a traditional Chinese medicine nano preparation. The traditional Chinese medicine nano preparation comprises nobiletin, formononetin and a carrier. According to the traditional Chinese medicine nano preparation, the nobiletin and the formononetin are entrapped in the carrier to form the nano particles with uniform particle size and good dispersity, so that the problems of poor water solubility and low bioavailability of the medicine can be effectively improved, the lung targeted delivery is enhanced, and the residence time of the medicine in the lung is prolonged. According to the traditional Chinese medicine nano preparation, the expression of ZO-1, OCLN, E-cad and other connexins is remarkably improved by inhibiting the EGFR pathway, the alveolar epithelial barrier structure and function are protected, and the inflammatory response and oxidative stress induced by PM2.5 are relieved, so that the lung injury induced by PM2.5 is effectively prevented and treated.

The application provides a kind of nasal mucosa in vitro culture method and culture fluid, the composition of the culture fluid includes Wnt / β-catenin signal pathway activator 0.1-20 μg / ml, fibroblast growth factor 10-150 ng / ml, TGF-β inhibitor 0.02-3 μg / ml, ROCK inhibitor 0.1-100 μmol / L, P38 MAPK inhibitor 0.1-1 μmol / L, serum-free additive 1X, N-acetyl cysteine 1-10 mmol / L, nicotinamide 1-20 mmol / L, GlutaMax additive 1X, antibiotic, DMEM / F12 culture medium 1X.The application can carry out in vitro culture to nasal mucosa, can keep at least 2 weeks of activity, and have complete epithelial barrier and immune system, can realize ex vivo nasal mucosa virus infection experiment.

The application discloses a traditional Chinese medicine composition with the effect of treating infantile recurrent respiratory tract infection and a preparation method thereof. Through a large amount of clinical practice, the application selects radix pseudostellariae, fried atractylodes, fried rhizoma atractylodis, agastache, levisticus, lonicera, radix scrophulariae, carbonized wheat bran, calcined osseous, ephedra root as raw materials, and is prepared into an oral or external dosage form according to weight ratio. The application has the effects of transporting the spleen, preventing the invasion of pathogenic factors, and consolidating the surface and stopping sweating, and is used for infantile recurrent respiratory tract infection with the syndrome of the spleen failing to transport and the lung and defensive system failing to consolidate. The application is verified by clinical tests, has remarkable curative effect, no toxic side effect, and good safety. Animal experiment researches show that the traditional Chinese medicine composition can effectively relieve the chronic inflammation level of model mice, improve the airway epithelial barrier damage, improve the body's ability to resist pathogenic factors, and reduce the risk of infection. The application can fill the market blank of treating infantile recurrent respiratory tract infection diseases based on the theory of 'four seasons with the spleen being strong and not being invaded by pathogenic factors' and 'the spleen being strong is not about tonifying but about transportation', and has great development prospect.

The application belongs to the technical field of medicines, and particularly relates to application of alpha-asarone in preparation of a medicine for treating allergic rhinitis. The application aims at the problems of single drug target, prominent safety hazards and inability to block pathological progress from the root in the existing medicines for treating allergic rhinitis, takes alpha-asarone as an active ingredient, inhibits excessive activation of an inflammation pathway by activating an Nrf2 / HO-1 signal axis, and bidirectionally regulates expression balance of GPX4 and ACSL4 to inhibit ferroptosis and damage of a nasal epithelial barrier. Animal experiments prove that the alpha-asarone can significantly reduce allergic behaviors of model mice, relieve inflammation of nasal mucosa, reverse tissue remodeling, has high safety, and can be prepared into oral or nasal preparations, and provides a new treatment scheme with multiple target points for allergic rhinitis.

The invention belongs to the technical field of animal nutrition and feed, discloses an application of a Fuzhuan tea extract in prevention of vomitoxin-caused piglet health injury, and particularly relates to an application of the Fuzhuan tea extract as a feed additive in prevention or improvement of piglet health injury. The feed additive can effectively reduce negative effects on weaned piglets caused by excessive vomitoxin in the feed, wherein the negative effects comprise growth performance reduction, diarrhea rate increase, intestinal morphology damage, intestinal cell proliferation inhibition, intestinal epithelial barrier injury, immune disorder, abnormal liver function and excessive oxidative stress and inflammatory response.

The invention discloses a compound traditional Chinese medicine water decoction for protecting an airway epithelial barrier and a preparation method and application thereof, the compound traditional Chinese medicine water decoction is a water decoction of a herba epimedii and fructus ligustri lucidi medicine pair, the compound traditional Chinese medicine water decoction comprises 7-14 parts by weight of herba epimedii and 7-14 parts by weight of fructus ligustri lucidi, the herba epimedii adopts roasted herba epimedii, and the fructus ligustri lucidi adopts wine fructus ligustri lucidi. The compound traditional Chinese medicine water decoction not only can inhibit airway epithelial cell apoptosis and relieve airway epithelial injury, but also can up-regulate expression of epithelial connexin caused by inflammatory injury, so that the epithelial barrier function is improved, the airway epithelial barrier steady state is maintained, and pathogens and allergens are prevented from entering. The use and popularization of the compound traditional Chinese medicine water decoction not only contribute to preventing airway inflammation, but also can relieve the incidence and severity of chronic and refractory respiratory system diseases, and has important significance for perfecting the treatment strategy of the existing respiratory system inflammatory diseases and improving the control rate.

The present invention relates to vaginal pharmaceutical compositions and methods and uses thereof, including: treating and preventing genital inflammation in a subject; modulating the level of one or more of Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus gardneri, Lactobacillus jensenii, and Lactobacillus iners in the genital microbiome of a subject; and maintaining or improving the integrity of the cervical-vaginal epithelial barrier in a subject.

The invention discloses a bionic gastric mucosa micro-barrier structure, comprising: a bottom microfluidic channel for simulating a submucosal vascular network; the middle gastric epithelial cell layer is used for simulating a mucous membrane epithelial barrier and comprises a matrix layer, quaternary functional cells, a culture medium and a pH buffer module; and the surface dynamic mucus layer is used for simulating a mucous membrane protective barrier and comprises a vagus neurotransmitter simulant, exogenous mucus and a pressure sensor. According to the invention, continuous nutrition supply is provided for the middle gastric epithelial cell layer through the bottom microfluidic channel, the survival and functions of cells are maintained, and accurate tracking of the transgastric mucosa transport process is realized. A function collaborative network is formed through quaternary cells, the secretion volume and the injury state are monitored in real time, regulatory factors are dynamically adjusted, and it is ensured that a cell layer can still maintain the barrier function stable under external interference. When foreign matter impact or food friction signals are recognized through the pressure sensor, the pump speed is instantly increased, and local mucus loss is rapidly supplemented.

The application discloses a kind of drug composition of synergistic targeting MMP-9 path and STING path and application thereof, belong to the technical field of ophthalmic drugs.The drug composition includes the final concentration 5~90 μM of Marimastat, the final concentration 2.5~10 μM of SN-011, the final concentration 0.1 vol % of DMSO and sterile PBS buffer solution.The drug composition of the application can efficiently, safely treat moderate to severe dry eye, effectively improve tear film stability, repair corneal epithelial barrier, inhibit ocular surface chronic inflammation, while reducing the risk of disease recurrence.

The invention discloses a bronchial asthma treatment drug based on RBX1 inhibition and application thereof, and finds that expression of RBX1 in asthma patients and disease models is up-regulated, and the expression level of RBX1 is in positive correlation with airway epithelial barrier injury and active oxygen accumulation degree, which indicates that RBX1 is a key new target for asthma treatment. On the basis of the compound Z226407860 and the compound Z4189742053, the condition that the expression of the RBX1 can be effectively inhibited is further proved. In an in-vitro model, the compounds not only significantly reduce the protein level of RBX1, but also show a good synergistic treatment effect: the compounds can effectively relieve the injury of the airway epithelial barrier and promote the integrity recovery of the barrier, and can inhibit the excessive accumulation of active oxygen at the same time, so that the asthma process is intervened from two correlative core pathological links. The research provides a solid experimental basis and a candidate compound with a clear prospect for developing a therapeutic drug which aims at bronchial asthma and has a brand new action mechanism.

The present disclosure relates to therapeutic proteins and pharmaceutical compositions containing the proteins that are useful for treating various human diseases. In certain aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with impaired epithelial cell barrier function or integrity. Furthermore, the disclosed therapeutic proteins are useful for treating human inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, among others.

The invention relates to the technical field of microorganisms, and discloses a bacterial strain capable of promoting intestinal health of children and application of the bacterial strain, the bacterial strain is separated from dairy products and is named as a Bifidobacterium animalis subsp. Lactis BB1000 bacterial strain, and the bacterial strain is named as Bifidobacterium animalis subsp. Lactis BB1000 bacterial strain and is named as Bifidobacterium animalis subsp. Lactis BB1000 bacterial strain. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30861, and the preservation date is June 5, 2024; the strain is resistant to acid and bile salt, has an antibacterial effect, has a function of enhancing intestinal epithelial barrier, and has an anti-inflammatory effect; the strain can be applied to probiotic lozenges.

The invention discloses an inflammation-responsive polypeptide prodrug and application thereof. The polypeptide prodrug is formed by covalently connecting a hydrophilic mucus penetration enhancement module (polyethylene glycol), a hydrophobic inflammation-responsive triggering module (glycinated phenylboronic acid pinacol ester), anti-inflammatory polypeptide (KPV, Ac-QAW or IRW) and a triggering self-destruction skeleton (phosphonitrilic chloride trimer). The prodrug can be self-assembled in an aqueous solution to form micellar nanoparticles with the particle size of 40-100 nm. After being orally taken, the composition can resist gastrointestinal tract enzymolysis and acidic environment damage, penetrates through an intestinal mucous layer through the permeation enhancement effect of polyethylene glycol, and starts a skeleton self-destruction cascade degradation reaction and accurately releases anti-inflammatory polypeptide under the triggering of high active oxygen at an inflammation part. The prodrug can effectively repair the intestinal epithelial barrier, inhibit oxidative stress reaction, inflammatory factor generation, neutrophil infiltration and extracellular trap formation, and promote M2 polarization and Treg cell differentiation of macrophages, so that efficient oral delivery of polypeptide drugs and treatment of inflammatory bowel diseases are realized.

The present application discloses use of FcgammaRIIB as an IgG transport receptor in mammary gland of mammals, and belongs to the field of biotechnology. FcgammaRIIB knockout mice and FcgammaRIIB knockout pigs are constructed, and the ratio of mammalian serum IgG to milk IgG in the FcgammaRIIB knockout mice is significantly increased, indicating a decrease in relative milk IgG concentration. Although mammalian serum IgG content is significantly increased in the FcgammaRIIB knockout pigs, IgG in colostrum of mammals is nearly undetectable. Therefore, the present application demonstrates for the first time that FcgammaRIIB serves as the receptor mediating transport of mammalian serum IgG across the mammary epithelial barrier into milk, which addresses a long-standing unresolved issue in the field of maternal passive immunity. Furthermore, the present application provides a new strategy for increasing colostrum IgG content, thereby enhancing early immunity and survival rate of newborn livestock.

The invention relates to the technical field of biology, in particular to a polygonum viviparum general flavone extraction method and application, in the extraction method, multiple factors are screened, the method with the highest extraction efficiency is obtained, and the method has the advantages of being high in extraction rate, low in cost, easy and convenient to operate, safe, environmentally friendly and the like, and is high in comprehensive cost performance and suitable for large-scale production; the polygonum viviparum general flavone can restore the reduction of the thickness of an intestinal mucosa layer and enhance the intestinal barrier function by adjusting the level of inflammatory cytokines so as to protect the intestinal tract of an LPS-induced enteritis mouse; the effect of the DSS on the abundance of the microflora is reversed, the effects of regulating the intestinal flora and repairing the intestinal epithelial barrier injury are achieved, and the potential effects of treating the intestinal epithelial barrier injury, the intestinal flora disorder and the uric acid level abnormity in digestive tract diseases are achieved; the compound is expected to be further developed into a pure natural plant flavonoid medicinal preparation for treating digestive tract diseases.

The invention discloses application of asperuloside in preparation of a medicine for preventing and / or treating intestinal epithelial barrier injury. The intestinal epithelium injury mouse model is constructed, and the asperuloside is adopted for administration treatment, so that the asperuloside can promote the intestinal epithelium regeneration of the intestinal epithelium injury animal model, enhance the effect of intestinal stem cells and remarkably promote the expression of a colon regeneration marker and a colon stem cell marker; the compound can be used for preventing and / or treating the intestinal epithelial barrier injury caused by intestinal inflammation, can protect the intestinal tract and relieve intestinal dysfunction, provides more effective medicines for maintaining the intestinal barrier function in clinic, and has important significance in preventing and treating the intestinal epithelial barrier injury caused by the intestinal inflammation and UC.

The invention discloses application of allicin combined with a propolis alcohol extract and a propolis water extract in preparation of a cryptosporidiosis-resistant medicine. The product is used for treating and preventing intestinal infection caused by cryptosporidium parvum, and is particularly suitable for preventing and treating cryptosporidiosis of patients with immunocompromise. Experimental results show that the ABP can effectively interfere with energy metabolism of insect bodies. The compound can significantly inhibit cryptosporidium proliferation, and shows low cytotoxicity. Meanwhile, the compound can enhance the integrity of intestinal epithelial barriers and promote mucous membrane structure repair. In an infected mouse model, the excretion amount of fecal oocysts is remarkably reduced through ABP treatment, and the pathological condition of the intestinal tract is remarkably improved. Serological analysis further shows that the ABP can regulate inflammation and antioxidant balance and inhibit excessive inflammatory response. An intestinal flora sequencing result also shows that the ABP and AWBP treatment can relieve flora structure disorder caused by infection, promote enrichment of beneficial flora and inhibit pro-inflammatory related flora.

The invention provides a method of delivering a payload molecule across an epithelial tissue barrier, the method comprising: applying the payload molecule to the epithelial tissue barrier, and additionally applying an agent to the epithelial tissue barrier. The agent is (i) a microbial quorum sensing signalling molecule (microbial QSSM) or a derivative or variant thereof, which is capable of disrupting the epithelial tissue barrier function, or (ii) a carboxylic acid compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

The invention relates to an application of xanthohumol or a pharmaceutically acceptable derivative thereof in resisting throat reflux disease (LPRD) and a preparation of the xanthohumol or the pharmaceutically acceptable derivative thereof. The xanthohumol XN can be combined with pepsin active centers (such as Asp32 and Asp215), the secondary structure of the pepsin active centers is changed, and the proteolytic function of the pepsin active centers is blocked, so that the damage to the vocal cord epithelium barrier is reduced; the xanthohumol can reduce expression of proinflammatory factors (such as IL-1beta) by inhibiting an NF-kappa B / NLRP3 / IL-1beta inflammatory pathway, relieve inflammatory response of throat tissues, up-regulate expression of tight junction protein (ZO-1, E-cadherin) and recover integrity of a vocal cord epithelial cell connection structure. The preparation can be prepared into forms such as a film candy, an oral soluble film, a spray and a lozenge, directly acts on the throat part, is suitable for LPRD patients with non-acidic reflux as a main part, and has the advantages of strong targeting property, high safety of liver and kidney functions and the like.

The application discloses an oral drug delivery system targeting mesenteric lymph nodes, prepares a novel LNP oral delivery carrier simulating drug release of chylomicron, and explores a pathway and method of intestinal chylomicron lymphatic vessel targeting by modifying a carrier material with a targeting group. Compared with the prior art, the application can significantly improve the ability of nano-drugs to penetrate the intestinal epithelial barrier, enhance the targeting of nano-drugs, and has significant advantages in improving vaccine stability, enhancing immune response and reducing side effects through calcium alginate hydrogel wrapping.

The application belongs to the field of biological medicine, and particularly relates to application of an extract of Pteronura dumerelli in preparation of a medicine for treating ulcerative colitis, and aims to solve the technical problems of weak mucosa repair capacity, high recurrence rate after drug withdrawal, prominent long-term application safety problem, poor drug response or drug resistance of part of patients, and poor economic accessibility of existing ulcerative colitis treatment medicines. The preparation of the extract comprises the following steps: edible soft tissues of Pteronura dumerelli are washed with clean water to remove impurities, and then subjected to tissue crushing and homogenization treatment in a preset low-temperature environment; a compound enzyme system composed of neutral protease and papain is added to perform mild limited enzymolysis, and active small-molecule peptides and polysaccharide components are reserved; after low-temperature centrifugation to remove precipitates, two-stage ultrafiltration membranes are used for grading purification, high-activity small-molecule anti-inflammatory repair components are enriched, and finally low-temperature vacuum concentration and sterile filtration are performed to obtain a light yellow water-soluble active extract. The extract can inhibit activation of a nuclear factor kappa B inflammatory pathway, down-regulate levels of tumor necrosis factor alpha, interleukin 6 and interleukin 1 beta proinflammatory factors, reduce intestinal inflammatory cascade reaction, up-regulate expression of tight junction proteins Occludin and Claudin-1, repair damaged intestinal epithelial barrier, promote ulcer mucosa regeneration and healing, and realize a double synergistic treatment effect of anti-inflammation and mucosa repair.